{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:43:10Z","timestamp":1791474190954,"version":"4.3.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Tralokinumab, a monoclonal anti-IL-13 antibody, is approved for treating atopic dermatitis (AD). Real-world data on its effectiveness and safety are limited.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    To evaluate the real-world effectiveness and safety of tralokinumab and the transition of laboratory indexes during 24-week treatment for AD patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    This retrospective study included 104 patients with moderate-to-severe AD treated with tralokinumab 300 mg every 2 weeks after primary 600 mg. Clinical and laboratory indexes were assessed until week 24.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    At week 24, achievement rates of Eczema Area and Severity Index 75 (EASI 75), EASI 90, and investigator\u2019s global assessment 0 out of 1 in systemic therapy-na\u00efve patients, 83.3%, 72.2%, and 44.4%, respectively, were higher than those in systemic therapy-experienced patients, 46.7%, 20.0%, and 6.7%, respectively. Serum levels of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), and lactate dehydrogenase (LDH) significantly decreased at week 24, whereas neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation response index (SIRI) significantly decreased at week 12 from baseline. Twenty-nine patients (27.9%) experienced mild treatment-emergent adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Conclusions:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Tralokinumab treatment showed prosperous therapeutic effects and good tolerability in real-world practice for AD, with higher effectiveness in patients without prior systemic therapy compared with those with prior systemic therapy. Tralokinumab treatment significantly decreased clinical and laboratory indexes, EASI, Peak Pruritus-Numerical Rating Scale, IgE, TARC, LDH, NLR, and SIRI.\n                  <\/jats:p>","DOI":"10.1089\/derm.2024.0323","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T12:13:56Z","timestamp":1727957636000},"page":"235-243","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Onda","sequence":"additional","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic, Funabashi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"From the,  Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.008"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155664"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2019.08.009"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000499431"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13160"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1858802"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0627"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00702-2"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20832"},{"issue":"2","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4168\/aair.2017.9.2.158","article-title":"Clinical diversity of atopic dermatitis: A review of 5,000 patients at a single institute","volume":"9","author":"Chu H","year":"2017","unstructured":"Chu H, , Shin JU, , Park CO, et al. Clinical diversity of atopic dermatitis: A review of 5,000 patients at a single institute. Allergy Asthma Immunol Res., 2017; 9(2):158\u2013168; doi: 10.4168\/aair.2017.9.2.158","journal-title":"Allergy Asthma Immunol Res."},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000198"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1365544"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2310643"},{"issue":"4","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"e13457","DOI":"10.1111\/dth.13457","article-title":"Neutrophil\/platelet to lymphocyte ratio in monitoring of response to TNF-\u03b1 inhibitors in psoriatic patients","volume":"33","author":"Najar Nobari N","year":"2020","unstructured":"Najar Nobari N, , Shahidi Dadras M, , Nasiri S, et al. Neutrophil\/platelet to lymphocyte ratio in monitoring of response to TNF-\u03b1 inhibitors in psoriatic patients. Dermatol Ther., 2020; 33(4):e13457; doi: 10.1111\/dth.13457","journal-title":"Dermatol Ther."},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2013.834498"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13061"},{"issue":"3","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12030974","article-title":"Biomarkers and predictive factors for treatment response to tumor necrosis factor-\u03b1 inhibitors in patients with psoriasis","volume":"12","author":"Hagino T","year":"2023","unstructured":"Hagino T, , Saeki H, , Kanda N. Biomarkers and predictive factors for treatment response to tumor necrosis factor-\u03b1 inhibitors in patients with psoriasis. J Clin Med., 2023; 12(3); doi: 10.3390\/jcm12030974","journal-title":"J Clin Med."},{"issue":"1","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","article-title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan","volume":"35","author":"Hagino T","year":"2024","unstructured":"Hagino T, , Saeki H, , Fujimoto E, et al. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatolog Treat., 2024; 35(1):2307489; doi: 10.1080\/09546634.2024.2307489","journal-title":"J Dermatolog Treat."},{"issue":"4","key":"e_1_3_1_26_2","first-page":"e262","article-title":"The neutrophil-lymphocyte ratio in children with atopic dermatitis: A case-control study","volume":"168","author":"Dogru M","year":"2017","unstructured":"Dogru M, , Citli R. The neutrophil-lymphocyte ratio in children with atopic dermatitis: A case-control study. Clin Ter., 2017; 168(4):e262\u2013e265; doi: 10.7417\/t.2017.2017","journal-title":"Clin Ter."},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.900212"},{"issue":"2","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12098-012-0810-0","article-title":"Circulating immunoglobulins, leucocytes and complements in childhood-onset atopic eczema","volume":"80","author":"Hon KL","year":"2013","unstructured":"Hon KL, , Wang SS, , Pong NH, et al. Circulating immunoglobulins, leucocytes and complements in childhood-onset atopic eczema. Indian J Pediatr., 2013; 80(2):128\u2013131; doi: 10.1007\/s12098-012-0810-0","journal-title":"Indian J Pediatr."},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17186"},{"issue":"7","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"adv00491","DOI":"10.2340\/00015555-3838","article-title":"Role of eosinophil relative count and neutrophil-to-lymphocyte ratio in the assessment of severity of atopic dermatitis","volume":"101","author":"Inokuchi-Sakata S","year":"2021","unstructured":"Inokuchi-Sakata S, , Ishiuji Y, , Katsuta M, et al. Role of eosinophil relative count and neutrophil-to-lymphocyte ratio in the assessment of severity of atopic dermatitis. Acta Derm Venereol., 2021; 101(7):adv00491; doi: 10.2340\/00015555-3838","journal-title":"Acta Derm Venereol."},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12083046"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323174"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5701949"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179553"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13230"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.06.009"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19382"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01143-x"},{"issue":"5","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1111\/jdv.18753","article-title":"Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study","volume":"37","author":"Pezzolo E","year":"2023","unstructured":"Pezzolo E, , Naldi L. Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study. J Eur Acad Dermatol Venereol., 2023; 37(5):e644\u2013e645; doi: 10.1111\/jdv.18753","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad038"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"issue":"6","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2\u2009years","volume":"79","author":"Guttman-Yassky E","year":"2024","unstructured":"Guttman-Yassky E, , Kabashima K, , Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2\u2009years. Allergy., 2024; 79(6):1560\u20131572; doi: 10.1111\/all.16108","journal-title":"Allergy."},{"key":"e_1_3_1_43_2","article-title":"Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan","author":"Hagino T","year":"2024","unstructured":"Hagino T, , Onda M, , Saeki H, et al. Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan. Eur J Dermatol., 2024; doi: in press","journal-title":"Eur J Dermatol."},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.002"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12440"},{"issue":"4","key":"e_1_3_1_46_2","doi-asserted-by":"crossref","first-page":"L907","DOI":"10.1152\/ajplung.00120.2003","article-title":"IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: Role of IL-4 receptor genotype","volume":"285","author":"Faffe DS","year":"2003","unstructured":"Faffe DS, , Whitehead T, , Moore PE, et al. IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: Role of IL-4 receptor genotype. Am J Physiol Lung Cell Mol Physiol., 2003; 285(4):L907\u2013L914; doi: 10.1152\/ajplung.00120.2003","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214307"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062201"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"issue":"2","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.alit.2022.09.005","article-title":"Biologics for allergy: Therapeutic potential for ocular allergic diseases and adverse effects on the eye","volume":"72","author":"Fukuda K","year":"2023","unstructured":"Fukuda K, , Kishimoto T, , Sumi T, et al. Biologics for allergy: Therapeutic potential for ocular allergic diseases and adverse effects on the eye. Allergol Int., 2023; 72(2):234\u2013244; doi: 10.1016\/j.alit.2022.09.005","journal-title":"Allergol Int."}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2024.0323","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2024.0323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:09:04Z","timestamp":1777399744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2024.0323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5,1]]}},"alternative-id":["10.1089\/derm.2024.0323"],"URL":"https:\/\/doi.org\/10.1089\/derm.2024.0323","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}